{"analyses":[{"ciLowerLimit":"1.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Odds Ratio (OR)","paramValue":"2.6","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.8","upperLimit":"68.3","value":"60.7"},{"groupId":"OG001","lowerLimit":"32.1","upperLimit":"47.4","value":"39.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"167"}],"units":"Participants"}],"description":"Defined as percentage of participants achieving RBC-TI for \\>= 168 days during any consecutive 168-day period from Week 1 through Week 48.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"NUMBER","populationDescription":"ITT Population (all randomized participants regardless of whether or not the participant received treatment) whose first dose date is at least 337 days from the cutoff date or discontinued early are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 48","title":"Percentage of Participants Achieving Red Blood Cell Transfusion Independence (RBC-TI) for a Consecutive 24-week Period","type":"SECONDARY","unitOfMeasure":"Percent of participants"}